Aura Biosciences, Inc.
AURA
$7.67
$0.020.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.29M | 23.71M | 22.49M | 22.62M | 23.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 138.08M | 118.62M | 112.79M | 113.36M | 108.69M |
| Operating Income | -138.08M | -118.62M | -112.79M | -113.36M | -108.69M |
| Income Before Tax | -130.93M | -112.29M | -106.08M | -106.35M | -101.25M |
| Income Tax Expenses | 81.00K | 100.00K | 107.00K | 116.00K | 133.00K |
| Earnings from Continuing Operations | -131.01 | -112.39 | -106.19 | -106.47 | -101.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.01M | -112.39M | -106.19M | -106.47M | -101.38M |
| EBIT | -138.08M | -118.62M | -112.79M | -113.36M | -108.69M |
| EBITDA | -136.99M | -117.51M | -111.66M | -112.21M | -107.51M |
| EPS Basic | -1.76 | -1.74 | -1.79 | -1.93 | -1.96 |
| Normalized Basic EPS | -1.10 | -1.09 | -1.12 | -1.20 | -1.22 |
| EPS Diluted | -1.76 | -1.74 | -1.79 | -1.93 | -1.96 |
| Normalized Diluted EPS | -1.10 | -1.09 | -1.12 | -1.20 | -1.22 |
| Average Basic Shares Outstanding | 295.35M | 258.50M | 241.18M | 224.02M | 207.74M |
| Average Diluted Shares Outstanding | 295.35M | 258.50M | 241.18M | 224.02M | 207.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |